Nestmedic

Nestmedic ROCE

The Return on Capital Employed (ROCE) of Nestmedic (NST.WA) as of Oct 28, 2026 is -50.78 %. In the previous year, Return on Capital Employed (ROCE) was -163.87 % — a change of -69.01% (higher).

ROCE

-50.78 %

YoY

-69.01%

Last updated:

In 2025, Nestmedic's return on capital employed (ROCE) was -50.78 %, a -69.01% increase from the -163.87 % ROCE in the previous year.

The Nestmedic ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
0.00 PLN
Jan 1, 2019
0.05 PLN
Jan 1, 2020
-0.00 PLN
Jan 1, 2021
-358.69 PLN
Jan 1, 2022
-201.80 PLN
Jan 1, 2023
-117.82 PLN
Jan 1, 2024
-163.87 PLN
Jan 1, 2025
-50.78 PLN
The Nestmedic ROCE history
YEARROCEYoY
-50.78 %-69.01%
-163.87 %+39.09%
-117.82 %-41.61%
-201.80 %-43.74%
-358.69 %+239.01 M%
-0.00-100.31%
0.05 %+29,291.24%
0.00-100.00%
-79.67 %+26.92%
-62.77 %-112.37%
507.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nestmedic Stock analysis

What does Nestmedic do? Nestmedic SA generates revenue through the sale of its Pregnabit telemedicine CTG device, which includes the display device, fetal heart rate probe, wrist heart rate monitor, tocodynamometer probe, and fetal movement marker. The company targets healthcare providers and clinics that require home-based fetal monitoring solutions, enabling pregnant women to conduct CTG tests independently. Medical Telemonitoring Center (MTC) processes the wireless data from Pregnabit, providing medical analysis and opinions to users. Nestmedic SA's product is designed for direct consumer use in home settings with professional medical oversight. The Pregnabit solution is marketed to healthcare institutions seeking to offer remote fetal health monitoring services. By eliminating the need for in-person specialist visits, the device supports cost-effective maternal care. MTC serves as the central hub for data analysis, ensuring medical professionals can interpret results and deliver timely advice without direct patient interaction. Nestmedic SA focuses on the development and production of this integrated telemedicine system for fetal monitoring. Nestmedic SA's business model relies on selling the Pregnabit device and associated hardware to healthcare facilities. The wireless transmission of data to MTC allows for continuous medical supervision without requiring patients to visit clinics. The company's core offering combines hardware, software, and medical analysis services to provide a comprehensive solution for home-based fetal health monitoring. Nestmedic is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Nestmedic's Return on Capital Employed (ROCE)

Nestmedic's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Nestmedic's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Nestmedic's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Nestmedic’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Nestmedic stock

Return on Capital Employed (ROCE) of Nestmedic is -50.78 % in 2025.

Return on Capital Employed (ROCE) of Nestmedic changed from -163.87 % to -50.78 %, representing a -69.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Nestmedic since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Nestmedic with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Nestmedic

All Key Metrics — Nestmedic